The treatment market for vasculitis, a rare inflammatory disease that changes the walls of blood vessels, is expected to see growth of a little more than five percent over the next 10 years, according to a new report from the research and consulting firm GlobalData.
The author of the report, GlobalData’s immunology analyst Alexandra Annis, explains this growth will happen due to the launch of five biologics with enhanced safety and efficacy profiles targeting different forms of the disease.Current treatment strategies for vasculitis tend to involve the use of immunosuppressants like Methotrexate and Prednisone, which Johns Hopkins notes can be associated with a long list of harmful side effects, such as scarring of the liver or low red blood cell count.
“The greatest unmet needs in the vasculitis market are improved safety and efficacy for both induction and maintenance therapies, as induction regimens for the management of vasculitis typically come with a considerable list of side effects, “adds the analyst.
Annis elaborates, saying that this new class of biologics will have four novel mechanisms of action (MOAs), which will benefit both patients and pharmaceutical companies.Patients won’t have to deal with burdensome side effects while drug makers could reap big profits — although Annis says that the high cost of these biologics could hinder uptake in cost-conscious markets.
Annis highlights three companies and their respective drug candidates as having the best chance of success: Roche’s Actemra, Bristol-Myers Squibb’s Orencia, and GlaxoSmithKline’s Nucala.Roche gained a breakthrough therapy designation for Actemra in June 2015 after demonstrating positive results in treating systemic sclerosis.
The FDA gave Nucala regulatory approval in November 2015 for treating a variant of severe asthma whereas Orencia aims to help patients with rheumatoid arthritis.
Date: January 6th, 2015